RNU6-1087P

Across TCGA pan-cancer cohorts, RNU6-1087P RNA is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated RNU6-1087P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNU6-1087P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-1087P expression acts as an unfavorable survival marker.

CHOL, KIRC, and PRAD are the cancer types where RNU6-1087P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	All	0.045	0.486	.009	45	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
PRAD	DFS	Tertile	All	0.717	0.936	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RNU6-1087P–CHOL (DFS)

Open the CHOL breakdown →